MIcronized PROgesterone in Frozen Embryo Transfer Cycles
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This randomized trial was designed as non-inferiority trial aiming to compare ongoing
pregnancy rates following LPS with 600 mg/day vs 800 mg/day vaginal VMP. All patients will
undergo an artificial cycle frozen embryo transfer (AC-FET) with transdermal estradiol
6mg/day Patients undergoing an artificial cycle FET will start estrogen priming with
transdermal estradiol 6mg/day (Estrogel®) on cycle D1-D3. Following 10-12 days of estrogen
priming, patients will be randomized to luteal phase support with a standard formulation
(200mg tid, Utrogestan®) or a new formulation (400mg bid) VMP. All patients will undergo a
serum P measurement on the day before embryo transfer (ET). Patients with P<10 ng/ml will
receive a supplement of oral micronized progesterone 300mg, while patients with P≥10ng/ml
will maintain the previous luteal phase support (LPS) protocol